Lessons from Monte Carlo Models: Why Drug Development is Hard
DrugBaron
FEBRUARY 16, 2024
“There is more than one way to skin a cat” is a rather gruesome British idiom, but its sentiment surely applies to running a successful pharmaceutical portfolio. So what does the game look like to a late-stage investor or a pharma company head of R&D thinking about portfolio prioritisation?
Let's personalize your content